15:32 , May 21, 2019 |  BC Extra  |  Company News

Merck bets on HIF2As with Peloton takeout ahead of planned listing

Days before Peloton was to price an IPO that would fund Phase III testing of its HIF2A program to treat kidney cancer, the biotech has elected instead to take a buyout offer from Merck &...
22:35 , May 17, 2019 |  BC Extra  |  Clinical News

May 17 Clinical Quick Takes: Achillion Phase III plans for PNH combo; plus NCI, MorphoSys

Achillion to start Phase III of PNH combo in 1H20  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will start in 1H20 a Phase III trial evaluating oral CFD inhibitor ACH-4471 in combination with C5 inhibitors to...
21:57 , May 16, 2019 |  BC Extra  |  Company News

Gilead defends Truvada pricing during House hearing

Chairman and CEO Daniel O'Day defended Gilead's pricing of HIV PrEP drug Truvada at a congressional hearing Thursday. Democrats led by House Oversight and Reform Committee Chair Elijah Cummings (D-Md.) pressed O'Day on the price...
23:56 , May 14, 2019 |  BC Extra  |  Tools & Techniques

May 14 P&P Quick Takes: German council weighs in on germline editing; plus Gilead’s Truvada, U.K. R&D tax

German committee outlines recs for human germline editing  The German Ethics Council took a positive stand towards eventual use of germline editing, with a report that starts to map a path forward; however, the council...
21:57 , May 10, 2019 |  BC Extra  |  Company News

May 10 Company Quick Takes: Red flags for Daiichi ahead of ODAC; plus JHL/Genentech, J&J, Gilead

FDA reviewers raise concerns about Daiichi’s quizartinib, pexidartinib  Despite both pexidartinib and quizartinib meeting the primary endpoints in their pivotal trials, FDA reviewers raised concerns about each agent from Daiichi Sankyo Co. Ltd. (Tokyo:4568) in...
14:31 , May 8, 2019 |  BC Extra  |  Company News

Gilead’s Goldfinch deal signals renewed optimism in kidney therapies

In the latest sign of that the kidney is regaining attention for drug developers, Gilead has tapped Goldfinch's drug discovery tools to co-develop therapies for diabetic kidney disease and orphan kidney diseases. Goldfinch Biopharma Inc....
19:25 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

ADORA2A identified as a thrombosis target

DISEASE CATEGORY: Cardiovascular INDICATION: Thrombosis Cell culture and mouse studies suggest agonizing ADORA2A could help treat thrombosis. In primary human and mouse neutrophils treated with IgG from patients with antiphospholipid syndrome (APS), which is associated...
22:52 , May 3, 2019 |  BC Extra  |  Company News

May 3 Company Quick Takes: NHS England, Acacia, Insys, Novo, AZ

NHS strikes deal aimed at eliminating HCV in England  NHS England partnered with Gilead Sciences Inc. (NASDAQ:GILD), Merck & Co. Inc. (NYSE:MRK) and AbbVie Inc. (NYSE:ABBV) to identify and treat individuals who are unaware they...
21:23 , May 3, 2019 |  BioCentury  |  Emerging Company Profile

Vineti: Keeping cell therapies on track

Drawing on its experience with CAR T cell therapies, Vineti has developed a cloud-based software platform that standardizes processes and drives down costs in the supply chain for personalized medicines. According to Vineti Inc. CEO...
00:06 , May 3, 2019 |  BC Extra  |  Company News

O’Day touts cell therapies as Gilead beats on EPS

On his first earnings call as CEO of Gilead, Daniel O'Day said more M&A and deals by the bellwether within cell therapy are "fundamental and essential" as the company reported 1Q19 earnings Thursday that beat...